ArticlePloS one2011
In vitro evolution of allergy vaccine candidates, with maintained structure, but reduced B cell and T cell activation capacity.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Evaluation of humoral and cellular immune responses induced by a novel YidRv subunit vaccine from hypervirulentBiotechnologia · 2026Article
- Anti-atopic dermatitis properties of Cordyceps militaris on TNFα/IFNγ-stimulated HaCaT cells and experimentally induced atopic dermatitis in mice.Physical activity and nutrition · 2020Article
- Egg Allergy: Diagnosis and Immunotherapy.International journal of molecular sciences · 2020Review
- Low-intensity tower climbing resistance exercise reduces experimentally induced atopic dermatitis in mice.Journal of exercise rehabilitation · 2019Article
- Allergen Valency, Dose, and FcεRI Occupancy Set Thresholds for Secretory Responses to Pen a 1 and Motivate Design of Hypoallergens.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- Molecular cloning, expression, IgE binding activities and in silico epitope prediction of Per a 9 allergens of the American cockroach.International journal of molecular medicine · 2016Article
- Effects of Cymbidium Root Ethanol Extract on Atopic Dermatitis.Evidence-based complementary and alternative medicine : eCAM · 2016Article
- Article
- Hypoallergenic derivatives of Fel d 1 obtained by rational reassembly for allergy vaccination and tolerance induction.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2014Article
- In Silico Prediction of T and B Cell Epitopes of Der f 25 in Dermatophagoides farinae.International journal of genomics · 2014Article
- Allergen Peptides, Recombinant Allergens and Hypoallergens for Allergen-Specific Immunotherapy.Current treatment options in allergy · 2014Review
- New vaccines for Mammalian allergy using molecular approaches.Frontiers in immunology · 2014Review
- Designing a multimer allergen for diagnosis and immunotherapy of dog allergic patients.PloS one · 2014Article
- Depigmented allergoids reveal new epitopes with capacity to induce IgG blocking antibodies.BioMed research international · 2013Article
- Safety of engineered allergen-specific immunotherapy vaccines.Current opinion in allergy and clinical immunology · 2012Review
- Vaccines for allergy.Current opinion in immunology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergy and asthma to cat (Felis domesticus) affects about 10% of the population in affluent countries. Immediate allergic symptoms are primarily mediated via IgE antibodies binding to B cell epitopes, whereas late phase inflammatory reactions are mediated via activated T cell recognition of allergen-specific T cell epitopes. Allergen-specific immunotherapy relieves symptoms and is the only treatment inducing a long-lasting protection by induction of protective immune responses. The aim of this study was to produce an allergy vaccine designed with the combined features of attenuated T cell activation, reduced anaphylactic properties, retained molecular integrity and induction of efficient IgE blocking IgG antibodies for safer and efficacious treatment of patients with allergy and asthma to cat. The template gene coding for rFel d 1 was used to introduce random mutations, which was subsequently expressed in large phage libraries. Despite accumulated mutations by up to 7 rounds of iterative error-prone PCR and biopanning, surface topology and structure was essentially maintained using IgE-antibodies from cat allergic patients for phage enrichment. Four candidates were isolated, displaying similar or lower IgE binding, reduced anaphylactic activity as measured by their capacity to induce basophil degranulation and, importantly, a significantly lower T cell reactivity in lymphoproliferative assays compared to the original rFel d 1. In addition, all mutants showed ability to induce blocking antibodies in immunized mice.The approach presented here provides a straightforward procedure to generate a novel type of allergy vaccines for safer and efficacious treatment of allergic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.